HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
Research in the Aplenc Lab centers on pediatric acute myeloid leukemia (AML) with ongoing translational, patient-centered outcomes research, and large data projects aimed at improving treatment options and clinical outcomes for children with AML.
Ongoing studies in the Aplenc lab include evaluating the AML blast surface to identify new therapy targets and the development of chimeric antigen receptor clinical trials for children with relapsed/refractory AML. The lab is also investigating genetic factors associated with the treatment complications of pediatric AML therapy using genome-wide genotyping and next generation sequencing.
In addition, the Aplenc Lab has several ongoing patient-centered outcomes research studies. These include a multi-center study of inpatient versus outpatient management after administration of AML chemotherapy. This study integrates medical outcomes with semi-structured interviews and quality of life survey data.
Finally, the Aplenc lab has multiple ongoing clinical epidemiology research studies utilizing and integrating multiple datasets. These include the analysis of clinical trial data from Children's Oncology Group (COG) Phase III trials, analyses of electronic medical record data from four leading pediatric institutions, analyses of administrative/billing data from the Pediatric Health Information Systems (PHIS), data from Medicare, registry data from the Center for International Blood and Marrow Transplant Research (CIBMTR), and several projects merging these data sets.
Richard Aplenc, MD, PhD, MSCE
Assistant Vice President and Chief Clinical Research Officer
Dr. Aplenc investigates ways to improve the outcomes of children with cancer, particularly acute myeloid leukemia, with clinical epidemiology studies and translational research.